

Innovative Medicines Initiative


WORKSHOP on ONCOLOGY

The goal of the workshop is to identify where an IMI programme could bring the most value in moving forward the oncology innovation agenda, taking into consideration the Spanish oncology community and opening a debate around the future.

Madrid, January 12th, 2017.

Venue: CNIO - Spanish National Cancer Research Centre. C/ Melchor Fernández Almagro, 3, Madrid.

Organized by:



MEDICAMENTOS INNOVADORES
Plataforma Tecnológica Española



Supported by:



AGENDA

09:15 – 9:45 Registration

09:45 – 10:15 Opening session

Marta Gómez Quintanilla. Spanish Representative of IMI. CDTI.

Ion Arocena. Director-General. ASEBIO.

Humberto Arnés. Director-General. Farmaindustria.

Jesús González. Director-General. ISCIII.

María Blasco. Director-General. CNIO.

10:15 – 10:45 Innovative Medicines Initiative

Pierre Meulien, IMI Executive Director.

10:45 – 11:30 An oncology strategy for IMI

Stefan J. Scherer, Global Head Translational Precision Medicine, Novartis; Chair of the IMI Strategic Governing Group (SGG) Oncology.

Carmen Eibe, Director, Project Coordination Department, PharmaMar.

11:30 – 11:45 Coffee break (Hall)

11:45 – 13:30 The perspectives of Spain

11:45 – 12:10 María Blasco, IMI Scientific Committee member, Director of the Spanish National Cancer Research Centre (CNIO).

12:10 – 13:00 Key speakers:

Andrés Cervantes, Jefe del servicio de oncología del Hospital Clínico Universitario de Valencia.

Joaquín Arribas, Scientific Director, Centro de Investigación Biomédica en Red en Oncología (CIBERONC).

Alfonso Valencia, Director Spanish National Bioinformatics Institute (INB).

13:00 – 13:30 Debate.

13:30 – 15:00 Lunch break (Cafeteria)***15:00 – 15:30 The perspectives of the European Commission***

Jan van de Loo, Scientific Officer, Non-communicable diseases and the challenge of healthy ageing, DG Research & Innovation, European Commission.

15:30 – 16:00 The perspectives of the Spanish Agency of Medicines and Medical Devices

César Hernández. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS).

16:00 – 16:30 Next steps and concluding remarks

Marta Gómez Quintanilla, Spanish Representative – Health & IMI – Horizon 2020, Centro para el Desarrollo Tecnológico Industrial.